{"name":"Suzhou Puhe Pharmaceutical Technology Co., LTD","slug":"suzhou-puhe-pharmaceutical-technology-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Pemetrexed+carboplatin/Cisplatin","genericName":"Pemetrexed+carboplatin/Cisplatin","slug":"pemetrexed-carboplatin-cisplatin","indication":"Non-small cell lung cancer (NSCLC)","status":"phase_3"},{"name":"YK-209A tablet","genericName":"YK-209A tablet","slug":"yk-209a-tablet","indication":"Metastatic non-small cell lung cancer","status":"phase_3"}]}],"pipeline":[{"name":"Pemetrexed+carboplatin/Cisplatin","genericName":"Pemetrexed+carboplatin/Cisplatin","slug":"pemetrexed-carboplatin-cisplatin","phase":"phase_3","mechanism":"Pemetrexed inhibits multiple folate-dependent enzymes to disrupt DNA synthesis, while carboplatin or cisplatin cross-link DNA strands, together inducing cancer cell death.","indications":["Non-small cell lung cancer (NSCLC)","Mesothelioma","Other solid tumors (phase 3 dependent)"],"catalyst":""},{"name":"YK-209A tablet","genericName":"YK-209A tablet","slug":"yk-209a-tablet","phase":"phase_3","mechanism":"YK-209A tablet is a small molecule that targets the PI3K/AKT signaling pathway.","indications":["Metastatic non-small cell lung cancer","Metastatic breast cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQSFdSY1Vwb1llTndlS2J6Yk5IR0Nsa2dfOFItczREZmg4SXg4c2ZsYjJwVXowdGdCRlVqYlFnbUNycUZkb1FFZDk3em1tVE1IY2ZMVmJjUS1nSlZFQTRuSy1QQ0JsUExwVWplRy1OM3NEaElsTW5kNnVUX0NLWW5zblowMlM4blJuSmNicnI1Y1VnX1d4eFpveW1mSQ?oc=5","date":"2026-03-24","type":"trial","source":"openPR.com","summary":"EGFR + NSCLC Clinical Trial Pipeline Accelerates as 25+ Pharma - openPR.com","headline":"EGFR + NSCLC Clinical Trial Pipeline Accelerates as 25+ Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxOal9XWURDaGNNRFhFZDY5YXBGeGlRTk1JY2VSS3RMOWctc2NHdGstT2NoLUI2QW5PQ2llaE16RVBZZzNfS01rbEsxZG1OeVlDaEtfRnJETjVlZjJSRHR6bUtacEVoRmE1U2UzdnRiajZkQWZZY2xkN0ZBSnFaQVZMWEEyQkU3UklwNG5FNGI1bngzZ2VkU0w4d3pWaEJESWRib0hPT0xGSzN4TmhVVTA5SUtPNkZremtsYmhqTEFtbGtIb0JjR1RZNDhNOWtrQ3ZJY1B2TldPemZMR1VXUDRhb0pGVTc?oc=5","date":"2025-04-02","type":"pipeline","source":"Yicai Global","summary":"Bayer Pharmaceuticals Prepares for a Landmark Year with Key Product Launches, Strategic Focus on China Amid Challenges - Yicai Global","headline":"Bayer Pharmaceuticals Prepares for a Landmark Year with Key Product Launches, Strategic Focus on China Amid Challenges","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOT1c4Qjd4cUZObU9yZlhJdjF6b0p5LXVPdmNWNnF6MURmNHhTUHU5TzQyWm5IWHlwc3NhLWVfeU5OdTB6Z2xnUVNQcFM4QUhiTzI2RGtPS1hCWndRUWxSR09PMEpBdU1wOWpmSzBqaUdqcnF5WUlrWHBMN19fcTNVaDkyZmc0R25fSFdv?oc=5","date":"2025-03-27","type":"deal","source":"Yahoo Finance","summary":"Bayer Licenses PRMT5 inhibitor From Suzhou Puhe BioPharma - Yahoo Finance","headline":"Bayer Licenses PRMT5 inhibitor From Suzhou Puhe BioPharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxQam9KRWVOOWo3TFI4S0gzTV9GanJ6ZlY1UGNkY2x1RVNZaDAzWlI1aDIycllUVjlQakVUZklQRkJ5QU90d3pVTExEV2JKVTBpREhNdEJqLW1PeERNd3lZYzFTV19vbzhBY2RTV3dLbGozRmozWndWbE1lUUdaR1lBeV9fa2NSb3R1d0tRVmFaZUVLSlFpRjJGUktELVROcHNvN0NxQUROdUpDZUVpREdpRkR6VldNN01jb1RXNDVVMzM4RE1mbXhwN0lKMTM?oc=5","date":"2025-03-26","type":"trial","source":"Bayer","summary":"Bayer and Puhe BioPharma enter into global license agreement for clinical phase I PRMT5 inhibitor - Bayer","headline":"Bayer and Puhe BioPharma enter into global license agreement for clinical phase I PRMT5 inhibitor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxNMjVPSUNNbHQ2WHNvaWEyaV9uT2ZpTDdLTHdPVmhEWTloTmgxVnQ1eTA2QWRYLWZwRnNEWWJnOFprNk1nVDNQOThwODlvSHRZTHhlcDdaU2JvaHBNNF9pYmVzc2hsNDhQYzJXbWI5Q1JscWZoX0Zfa280aGJGTlI5QnRva3oxTV96aDVlckthYnRXbGJubWxsMzF6SzZBb1M0Nk5zQ0IxLUEzeE5UUHdjbWVZVzczYnRHa3VlNHQwQnRlOXhoZzJZY2xNVE5vZnhZeGpidG9FTzEzeTJiYldBWEl6WURZeDJYZXBkZA?oc=5","date":"2025-03-11","type":"pipeline","source":"prnewswire.com","summary":"TAGRISSO Sets the Stage for Market Leadership in Oncology with Strong Growth Prospects | DelveInsight - prnewswire.com","headline":"TAGRISSO Sets the Stage for Market Leadership in Oncology with Strong Growth Prospects | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxOdVlhOFhDYnpBRGh4WlhFWG93ZHdmak5FZDVRVC1qWER1YlFhbnQ5TThBM0Y5ZjJaaExucGI2LVNsSmRUMDQ3cVBHT211N1JHVXNBRklDUTR1VjdITWkxSTA5OXNTMkZ2S3hnVDBMNHJYamp2Ri1UcHhBRlBLUWNxLXFMeHRlXzFpOXpkRzF4NlZWYlBGS0xqaGlHSlMzMkRFcG1tRjd4aU5sOE5TUWJvdklNd0F5YmZIMU91Tng5X0F3UlJESVI1M0tDaUFid2c1MjlhMlFiTHNGaUViTkN3b01pM2J4cndGY0NueG9VTTl0bGtmWF9KcEpZOVlodHZQWE5FbW1aNDBzTTNZTVNWTWpWZjhVM00zcHZIUV9sTQ?oc=5","date":"2025-01-14","type":"trial","source":"prnewswire.com","summary":"Non-Small Cell Lung Cancer Clinical Trial Pipeline Boom as Over 100 Companies Leading the Charge in Research and Development | DelveInsight - prnewswire.com","headline":"Non-Small Cell Lung Cancer Clinical Trial Pipeline Boom as Over 100 Companies Leading the Charge in Research and Develop","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}